Charles Schwab Investment Management Inc. Has $20.02 Million Stock Holdings in John Wiley & Sons, Inc. (NYSE:WLY)

Charles Schwab Investment Management Inc. lifted its stake in John Wiley & Sons, Inc. (NYSE:WLY) by 2.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 630,659 shares of the company’s stock after purchasing an additional 15,025 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in John Wiley & Sons were worth $20,017,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. Ceredex Value Advisors LLC acquired a new position in shares of John Wiley & Sons in the fourth quarter worth about $6,779,000. Vanguard Group Inc. boosted its stake in John Wiley & Sons by 2.3% in the 3rd quarter. Vanguard Group Inc. now owns 5,466,223 shares of the company’s stock worth $203,180,000 after purchasing an additional 123,637 shares during the period. Louisiana State Employees Retirement System purchased a new position in John Wiley & Sons during the 4th quarter worth approximately $676,000. Nordea Investment Management AB raised its stake in John Wiley & Sons by 72.6% during the 3rd quarter. Nordea Investment Management AB now owns 152,659 shares of the company’s stock valued at $5,781,000 after purchasing an additional 64,193 shares during the period. Finally, GSA Capital Partners LLP purchased a new stake in shares of John Wiley & Sons in the third quarter valued at $1,619,000. Hedge funds and other institutional investors own 73.94% of the company’s stock.

John Wiley & Sons Stock Performance

Shares of WLY stock opened at $37.90 on Friday. The company has a market capitalization of $2.07 billion, a price-to-earnings ratio of -13.16 and a beta of 0.89. John Wiley & Sons, Inc. has a 1-year low of $28.83 and a 1-year high of $40.23. The company has a current ratio of 0.54, a quick ratio of 0.50 and a debt-to-equity ratio of 1.20. The stock’s fifty day simple moving average is $37.95 and its 200-day simple moving average is $34.51.

John Wiley & Sons (NYSE:WLY) last issued its earnings results on Thursday, March 7th. The company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.14. The company had revenue of $460.70 million for the quarter, compared to the consensus estimate of $392.60 million. John Wiley & Sons had a positive return on equity of 18.83% and a negative net margin of 8.14%. The firm’s quarterly revenue was down 6.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.85 EPS. On average, sell-side analysts predict that John Wiley & Sons, Inc. will post 2.55 earnings per share for the current fiscal year.

John Wiley & Sons Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, April 25th. Shareholders of record on Tuesday, April 9th were paid a dividend of $0.35 per share. This represents a $1.40 dividend on an annualized basis and a dividend yield of 3.69%. The ex-dividend date of this dividend was Monday, April 8th. John Wiley & Sons’s dividend payout ratio (DPR) is currently -48.61%.

Insider Transactions at John Wiley & Sons

In related news, EVP Jay Flynn sold 6,114 shares of John Wiley & Sons stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $38.82, for a total transaction of $237,345.48. Following the completion of the sale, the executive vice president now owns 8,069 shares of the company’s stock, valued at $313,238.58. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.79% of the stock is currently owned by company insiders.

John Wiley & Sons Profile

John Wiley & Sons, Inc operates as a research and education company worldwide. The company operates through three segments: Research, Academic, and Talent. The company offers scientific, technical, medical, and scholarly journals, as well as related content and services to learned societies, individual researchers, other professionals, and academic, corporate, and government libraries.